CYP3A5 Gene-Guided Tacrolimus Treatment of Living-Donor Egyptian Kidney Transplanted Patients

• Ngā kaituhi matua: Effrosyni Mendrinou (Author), Mohamed Elsayed Mashaly (Author), Amir Mohamed Al Okily (Author), Mohamed Elsayed Mohamed (Author), Ayman Fathi Refaie (Author), Essam Mahmoud Elsawy (Author), Hazem Hamed Saleh (Author), Hussein Sheashaa (Author), George P. Patrinos (Author)
• Hōputu: Pukapuka
• I whakaputaina: Frontiers Media S.A., 2020-08-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

BackgroundTacrolimus is an approved first-line immunosuppressive agent for kidney transplantations. Part of interindividual and interethnic differences in the response of patients to tacrolimus is attributed to polymorphisms at CYP3A5 metabolic enzyme. CYP3A5 gene expression status is associated wit...